CR11386A - Productos quimioterapeuticos cristalinos - Google Patents

Productos quimioterapeuticos cristalinos

Info

Publication number
CR11386A
CR11386A CR11386A CR11386A CR11386A CR 11386 A CR11386 A CR 11386A CR 11386 A CR11386 A CR 11386A CR 11386 A CR11386 A CR 11386A CR 11386 A CR11386 A CR 11386A
Authority
CR
Costa Rica
Prior art keywords
crystal
chemotherapeutic products
chemotherapeutic
products
ways
Prior art date
Application number
CR11386A
Other languages
English (en)
Inventor
Michael J Rozema
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CR11386A publication Critical patent/CR11386A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forma cristalina 1 de N-(4-(3-amino-1H-indazol-4-il)fenil)-N'-(2-fluoro-5-metilfenil)urea toluenato, maneras para elaborarla y formas de usarla.
CR11386A 2007-10-19 2010-04-23 Productos quimioterapeuticos cristalinos CR11386A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98124307P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
CR11386A true CR11386A (es) 2010-08-18

Family

ID=40242659

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11386A CR11386A (es) 2007-10-19 2010-04-23 Productos quimioterapeuticos cristalinos

Country Status (20)

Country Link
US (1) US7943782B2 (es)
EP (1) EP2195297A1 (es)
JP (1) JP2011500706A (es)
KR (1) KR20100102098A (es)
CN (1) CN101827823B (es)
AU (1) AU2008312532A1 (es)
BR (1) BRPI0818343A2 (es)
CA (1) CA2699353A1 (es)
CO (1) CO6280483A2 (es)
CR (1) CR11386A (es)
DO (1) DOP2010000116A (es)
GT (1) GT201000101A (es)
MX (1) MX2010004289A (es)
MY (1) MY153098A (es)
PA (1) PA8800501A1 (es)
RU (1) RU2010119917A (es)
SG (1) SG185326A1 (es)
UA (1) UA99487C2 (es)
WO (1) WO2009052229A1 (es)
ZA (1) ZA201002092B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
BR112017002466A2 (pt) 2014-08-08 2017-12-05 Forsight Vision4 Inc formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005534633A (ja) * 2002-05-10 2005-11-17 テバ ファーマシューティカル インダストリーズ リミティド ガチフロキサシンの新規結晶形
WO2004101510A2 (en) * 2003-05-08 2004-11-25 Ivax Corporation Polymorphs of cabergoline
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
PT1638941E (pt) 2003-05-22 2010-08-24 Abbott Lab Inibidores de quinases de indazole, benzisoxazole e benzisotiazole
DE102005033100B3 (de) * 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) * 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
CN101346128B (zh) 2005-10-25 2013-10-02 雅培制药有限公司 包含低水溶解度药物的配方及其使用方法
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
CA2637838A1 (en) * 2006-01-20 2007-07-26 Janssen Pharmaceutica N.V. Novel solid forms of (4r)-1-¬4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl|-1,2,3,5-tetrahydro-spiro¬4h-1-benzazepine-4,1'-¬2|cyclopentene|-3'-carboxylic acid
CA2667720A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
AU2008312532A1 (en) 2009-04-23
JP2011500706A (ja) 2011-01-06
CN101827823A (zh) 2010-09-08
PA8800501A1 (es) 2009-05-15
CO6280483A2 (es) 2011-05-20
GT201000101A (es) 2012-03-26
ZA201002092B (en) 2011-11-30
MX2010004289A (es) 2010-04-30
MY153098A (en) 2014-12-31
UA99487C2 (xx) 2012-08-27
WO2009052229A1 (en) 2009-04-23
US20090105486A1 (en) 2009-04-23
US7943782B2 (en) 2011-05-17
CN101827823B (zh) 2012-10-03
SG185326A1 (en) 2012-11-29
CA2699353A1 (en) 2009-04-23
BRPI0818343A2 (pt) 2017-05-23
KR20100102098A (ko) 2010-09-20
EP2195297A1 (en) 2010-06-16
DOP2010000116A (es) 2010-05-31
RU2010119917A (ru) 2011-11-27

Similar Documents

Publication Publication Date Title
HN2005000722A (es) Forma termodinamicamente estable de una sal tosilato
CL2011002442A1 (es) Un compuesto n-(4-(4-(3-(3-terc-butil-1-p-tolil-1h-pirazol-5-il)ureido)naftalen-1-iloxi)piridin-2-il)-2-metoxiacetamida o una sal, estereoisomeros y tautomeros del mismo; composicion farmaceutica; y su uso para tratar o prevenir una afeccion seleccionada de epoc, asma e inhibicion del crecimiento y metastasis de tumores, entre otras.
EP1845086A4 (en) N-SUBSTITUTED N-METHOXYCARBAMATES BY 2-SUBSTITUTED PHENYL GROUPS, THEIR SYNTHESIS AND THEIR APPLICATIONS
CR11416A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
UY34161A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen
CL2011000242A1 (es) Uso de compuestos derivados de fenilaminopirimidina para tratar talasemia alfa, delta y anemia celular falciforme, talasemia mayor, talasemia menor, talasemia e-beta o talasemia beta falciforme, o para mejorar o retrasar los sintomas de las mismas y uso de un compuesto especifico para tratar la talasemia.
BR112012023525A2 (pt) método para preparar n-(4-cloro-3(triflúor metil)fenil)-n'-(4-(2-(n-(metil-d3)amino formil)-4-piridiloxi)fenil)uréia, intermediário, método para preparar 4-cloro-piridil-2-(n-(metil-d3))carboxamida, uso do intermediário e composto de ?-difenil uréia deuterada de p-tolueno sulfonato
HN2011002408A (es) Nueva forma cristalina vi de la agomelatina, preparacion y uso de la misma.
PL2201018T3 (pl) STAŁE POSTACIE ZAWIERAJĄCE N-(5-TERT-BUTYLOIZOKSAZOL-3-ILO)-N'-{4--[7-(2-MORFOLIN-4-YLOETOKSY)IMIDAZO[2,1-b][1,3]BENZOTIAZOL-2-ILO]FENYLO}MOCZNIK, ICH KOMPOZYCJE ORAZ ICH ZASTOSOWANIA
CR11386A (es) Productos quimioterapeuticos cristalinos
GT201000100A (es) Productos quimioterapéuticos cristalinos
ECSP10010175A (es) Productos quimioterapéuticos cristalinos
CL2008003091A1 (es) Forma cristalina 1 de etanolato de n-(4-(3-amino-1h-indazol-4il)fenil)-n-(2-fluoro-5-metilfenil)urea. 1/4; composicion farmaceutica; y uso en el tratamiento de cancer en un mamifero.
ECSP10010177A (es) Productos quimioterapéuticos cristalinos
UY31407A1 (es) "productos quimioterapéuticos cristalinos"
IL202737A0 (en) Urea and carbamate derivatives as non-nucleoside reverse transcriptase inhibitors
TH104744B (th) สารทางเคมีบำบัดที่เป็นผลึก
UA87361C2 (ru) КАЛИЙ N-(9-ФЛУОРЕНИЛИДЕН)-N'-м-АНИСОГИДРАЗОНАТ, КОТОРЫЙ ПРОЯВЛЯЕТ ПРОТИВОТУБЕРКУЛЕЗНОЕ ДЕЙСТВИЕ
ITRM20070018A1 (it) Sintesi del 2,5-diidrossitirosolo e suo uso
UA3849U (uk) Застосування моно- та дизаміщених амідів феназин-1-карбонової кислоти як інгібіторів micobacterium tuberculosis
TH104744A (th) สารทางเคมีบำบัดที่เป็นผลึก

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)